» Articles » PMID: 37762488

Beyond the Umbrella: A Systematic Review of the Interventions for the Prevention of and Reduction in the Incidence and Severity of Ovarian Hyperstimulation Syndrome in Patients Who Undergo In Vitro Fertilization Treatments

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Sep 28
PMID 37762488
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian hyperstimulation syndrome (OHSS) is the main severe complication of ovarian stimulation for in vitro fertilization (IVF) cycles. The aim of the current study was to identify the interventions for the prevention of and reduction in the incidence and severity of OHSS in patients who undergo IVF not included in systematic reviews with meta-analyses of randomized controlled trials (RCTs) and assess and grade their efficacy and evidence base. The best available evidence for each specific intervention was identified, analyzed in terms of safety/efficacy ratio and risk of bias, and graded using the Oxford Centre for Evidence-Based Medicine (CEBM) hierarchy of evidence. A total of 15 interventions to prevent OHSS were included in the final analysis. In the IVF population not at a high risk for OHSS, follitropin delta for ovarian stimulation may reduce the incidence of early OHSS and/or preventive interventions for early OHSS. In high-risk patients, inositol pretreatment, ovulation triggering with low doses of urinary hCG, and the luteal phase administration of a GnRH antagonist may reduce OHSS risk. In conclusion, even if not supported by systematic reviews with homogeneity of the RCTs, several treatments/strategies to reduce the incidence and severity of OHSS have been shown to be promising.

Citing Articles

Risk of Thrombosis in Women Undergoing In Vitro Fertilization: A Narrative Review.

Grandone E, Bitsadze V, Khizroeva J, Chinni E, Mastroianno M, Nappi L J Clin Med. 2025; 14(4).

PMID: 40004587 PMC: 11856335. DOI: 10.3390/jcm14041053.


Comparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome in women with polycystic ovary syndrome: a systematic review and network meta-analysis.

Lin L, Chen G, Qiao X, Chen Y, Deng H, Xu L J Ovarian Res. 2024; 17(1):249.

PMID: 39702393 PMC: 11657860. DOI: 10.1186/s13048-024-01576-0.


Live birth rate per fresh embryo transfer and cumulative live birth rate in patients with PCOS under the POSEIDON classification: a retrospective study.

Jiang L, Sun Y, Pan P, Li L, Yang D, Huang J Front Endocrinol (Lausanne). 2024; 15:1348771.

PMID: 38863934 PMC: 11165210. DOI: 10.3389/fendo.2024.1348771.


Metabolic landscape and pathogenic insights: a comprehensive analysis of high ovarian response in infertile women undergoing in vitro fertilization.

Ruan L, Lv X, Hu Y, Chen M, Jing-Tang , Zhong Z J Ovarian Res. 2024; 17(1):105.

PMID: 38760835 PMC: 11102248. DOI: 10.1186/s13048-024-01411-6.


Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.

Palomba S, Caserta D, Levi-Setti P, Busnelli A J Ovarian Res. 2024; 17(1):60.

PMID: 38486276 PMC: 10938807. DOI: 10.1186/s13048-024-01372-w.


References
1.
Turan G, Eskicioglu F, Nermin Sivrikoz O, Cengiz H, Gur E, Tatar S . Prophylactic vitamin D supplementation in ovarian hyperstimulation syndrome: an animal study. Arch Gynecol Obstet. 2015; 292(2):421-7. DOI: 10.1007/s00404-015-3625-1. View

2.
Hu K, Wang S, Ye X, Zhang D, Hunt S . GnRH agonist and hCG (dual trigger) versus hCG trigger for follicular maturation: a systematic review and meta-analysis of randomized trials. Reprod Biol Endocrinol. 2021; 19(1):78. PMC: 8167939. DOI: 10.1186/s12958-021-00766-5. View

3.
Tapanainen J, Lapolt P, Perlas E, Hsueh A . Induction of ovarian follicle luteinization by recombinant follicle-stimulating hormone. Endocrinology. 1993; 133(6):2875-80. DOI: 10.1210/endo.133.6.8243314. View

4.
Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

5.
Nakhuda G, Douglas N, Thornton M, Guarnaccia M, Lobo R, Sauer M . Anti-Müllerian hormone testing is useful for individualization of stimulation protocols in oocyte donors. Reprod Biomed Online. 2010; 20(1):42-7. DOI: 10.1016/j.rbmo.2009.10.009. View